Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMUXNYSE:JATTNASDAQ:ORMPNASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMUXImmunic$1.07-4.9%$1.08$0.83▼$2.11$102.05M1.73701,928 shs1.57 million shsJATTJATT Acquisition$1.44-2.0%$1.28$7.80▼$12.38$24.84MN/A41,322 shs197,404 shsORMPOramed Pharmaceuticals$2.23-3.5%$2.26$1.82▼$3.09$91.10M1.65154,247 shs32,425 shsVTYXVentyx Biosciences$1.21-12.3%$1.23$0.78▼$5.66$86.11M0.731.28 million shs1.45 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMUXImmunic-4.91%-16.80%+7.04%+8.13%-20.52%JATTJATT Acquisition-2.04%+5.11%+39.81%-23.40%-69.30%ORMPOramed Pharmaceuticals-3.46%-4.29%+6.19%+1.83%-10.44%VTYXVentyx Biosciences-12.32%-5.47%+28.75%-34.59%-74.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMUXImmunic2.4028 of 5 stars3.63.00.00.02.60.80.6JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals0.8422 of 5 stars0.03.00.00.00.60.81.9VTYXVentyx Biosciences2.3931 of 5 stars3.42.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMUXImmunic 3.25Buy$13.201,139.44% UpsideJATTJATT Acquisition 0.00N/AN/AN/AORMPOramed Pharmaceuticals 2.00HoldN/AN/AVTYXVentyx Biosciences 2.75Moderate Buy$10.00726.45% UpsideCurrent Analyst Ratings BreakdownLatest JATT, IMUX, ORMP, and VTYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/1/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/25/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform2/26/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.002/21/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/20/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMUXImmunicN/AN/AN/AN/A$0.64 per shareN/AJATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/AORMPOramed Pharmaceuticals$1.34M67.98N/AN/A$4.04 per share0.55VTYXVentyx BiosciencesN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%5/14/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AORMPOramed Pharmaceuticals$5.53M-$0.2120.27N/AN/AN/A-7.27%-6.20%5/8/2025 (Estimated)VTYXVentyx Biosciences-$192.96M-$1.98N/AN/AN/AN/A-54.94%-50.01%5/8/2025 (Estimated)Latest JATT, IMUX, ORMP, and VTYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025IMUXImmunic-$0.26N/AN/AN/AN/AN/A5/8/2025N/AORMPOramed Pharmaceuticals-$0.03N/AN/AN/AN/AN/A5/8/2025Q1 2025VTYXVentyx Biosciences-$0.48N/AN/AN/AN/AN/A3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/A2/27/2025Q4 2024VTYXVentyx Biosciences-$0.54-$0.41+$0.13-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMUXImmunicN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMUXImmunicN/A2.712.71JATTJATT AcquisitionN/A0.150.15ORMPOramed PharmaceuticalsN/A27.0827.08VTYXVentyx BiosciencesN/A23.5223.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMUXImmunic51.82%JATTJATT Acquisition47.97%ORMPOramed Pharmaceuticals12.73%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipIMUXImmunic3.00%JATTJATT Acquisition20.00%ORMPOramed Pharmaceuticals13.70%VTYXVentyx Biosciences18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMUXImmunic7095.82 million87.38 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableORMPOramed Pharmaceuticals1040.85 million34.79 millionOptionableVTYXVentyx Biosciences3071.16 million57.86 millionOptionableJATT, IMUX, ORMP, and VTYX HeadlinesRecent News About These CompaniesSusquehanna Fundamental Investments LLC Buys Shares of 198,947 Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 6 at 4:21 AM | marketbeat.comGreat week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous yearMay 4 at 2:12 PM | finance.yahoo.comVentyx Biosciences (VTYX) Projected to Post Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $690,000 Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 2, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)April 30, 2025 | marketbeat.comVentyx Biosciences announces seven additional appointments to SABApril 2, 2025 | markets.businessinsider.comVentyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease SpecialistsApril 1, 2025 | globenewswire.comVentyx Biosciences Reports 2024 Financial Results and ProgressMarch 4, 2025 | tipranks.comVentyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory ChallengesMarch 1, 2025 | tipranks.comH.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)February 28, 2025 | markets.businessinsider.comVentyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate ProgressFebruary 27, 2025 | globenewswire.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025February 18, 2025 | markets.businessinsider.comVentyx Biosciences’ VTX958 shows efficacy in Crohn’s DiseaseFebruary 18, 2025 | markets.businessinsider.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025February 18, 2025 | globenewswire.comVentyx Biosciences stock hits 52-week low at $1.57February 12, 2025 | msn.comVentyx Biosciences Inc (VTYX) Stock Settles at $1.84: What’s Contributing to This Price Point?February 5, 2025 | bovnews.comVentyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comWhy Ventyx Biosciences Inc (VTYX) Stock is Currently -1.57% Off from Its 20-Day SMA?January 23, 2025 | bovnews.comVTYX’s Latest Twist: What’s Fueling the Unexpected Shifts in Ventyx Biosciences Inc’s Stock Price?January 21, 2025 | bovnews.comVentyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. WainwrightJanuary 16, 2025 | markets.businessinsider.comVentyx Biosciences (VTYX) Gets a Hold from H.C. WainwrightJanuary 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJATT, IMUX, ORMP, and VTYX Company DescriptionsImmunic NASDAQ:IMUX$1.06 -0.06 (-4.91%) Closing price 05/6/2025 03:59 PM EasternExtended Trading$1.07 +0.00 (+0.09%) As of 05/6/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.JATT Acquisition NYSE:JATT$1.44 -0.03 (-2.04%) As of 05/5/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Oramed Pharmaceuticals NASDAQ:ORMP$2.23 -0.08 (-3.46%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$2.29 +0.06 (+2.69%) As of 05/6/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Ventyx Biosciences NASDAQ:VTYX$1.21 -0.17 (-12.32%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.83%) As of 05/6/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Top-Ranked Insider Buys From April by Market Cap Palantir Stock Drops Despite Stellar Earnings: What's Next? Hims & Hers Stock Rises on Fundamentals and Squeeze Potential Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership? D-Wave Quantum: Hidden Opportunity or Short Seller's Dream? Microsoft Stock After Xbox Price Hike: Buy or Hold? Uncertainty Creates Opportunity for Tyson Foods Investors Why Wells Fargo Is Buying $40 Billion of Its Own Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
